Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Outlook: Growth and Forecast Highlights 2030
Uncover key drivers, emerging technologies, and competitive movements shaping the metabolic dysfunction-associated steatohepatitis (mash) treatment market from 2026–2035 with trusted insights from The Business Research Company
What level of growth is expected in the Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market between 2026 and 2030?
The metabolic dysfunction-associated steatohepatitis (mash) treatment market size has experienced substantial growth in recent years. This market is anticipated to expand from $3.18 billion in 2025 to $3.88 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 22.2%. Several factors have driven its historical development, including the increasing prevalence of obesity, the rising incidence of type 2 diabetes, enhanced awareness of liver health disorders, improved diagnostic testing capabilities, and the early adoption of lifestyle modification programs.
The metabolic dysfunction-associated steatohepatitis (mash) treatment market size is projected for substantial expansion in the coming years, expected to reach $8.6 billion by 2030, driven by a compound annual growth rate (CAGR) of 22.0%. This anticipated growth can be credited to the rising adoption of GLP-1 agonists, advancements in antifibrotic drug development, increasing access to digital liver monitoring tools, broader utilization of bariatric surgery, and a growing emphasis on personalized metabolic therapies. Notable trends within this forecast period include the proliferation of precision liver disease therapeutics, AI-powered solutions for early detection and risk stratification, cloud-based systems for liver health data management, IoT-integrated approaches for lifestyle and medication monitoring, and the development of sustainable and preventive metabolic health programs.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=20876&type=smp
Which Drivers Are Expected To Impact The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market During The Forecast Period?
The rising incidence of obesity is expected to fuel the expansion of the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in the future. Obesity is a medical condition defined by an excessive accumulation of body fat that can adversely affect overall health, typically measured by a body mass index (BMI) of 30 or higher. The global prevalence of obesity is growing, primarily driven by sedentary lifestyles, unhealthy eating patterns, and metabolic risk factors. Metabolic Dysfunction-Associated Steatohepatitis (MASH) treatment in the context of obesity focuses on addressing insulin resistance, reducing liver fat, and improving metabolic health through lifestyle modifications and targeted therapies. For instance, in March 2023, according to the World Heart Foundation, a Switzerland-based non-government global cardiovascular community, roughly 2.3 billion adults and children worldwide are currently obese or overweight, and this figure is projected to reach 2.7 billion by 2025 if the current obesity trend continues. Therefore, the increasing prevalence of obesity is stimulating growth in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market.
Which Segments Are Driving Activity In The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
The metabolic dysfunction-associated steatohepatitis (mash) treatment market covered in this report is segmented –
1) By Treatment: Drug, Therapy
2) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
3) By End-User: Hospitals, Specialty Clinics, Homecare, Other End-User
Subsegments:
1) By Drug: Antifibrotic Agents, Antidiabetic Drugs, Lipid-Lowering Agents, Vitamin E, Obeticholic Acid (OCA), GLP-1 Agonists
2) By Therapy: Pharmacotherapy, Lifestyle Modifications (Dietary Changes, Exercise), Bariatric Surgery, Liver Transplantation
Which Competitive Trends Are Impacting The Structure Of The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
Leading companies in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market are concentrating on producing cutting-edge products, such as liver fibrosis treatment solutions, to offer therapeutic options for individuals afflicted with metabolic dysfunction-associated steatohepatitis (MASH) and moderate to severe liver fibrosis. These liver fibrosis treatment solutions primarily target the fundamental origins of liver damage through adjustments to lifestyle, antiviral drugs, and nascent antifibrotic treatments, with the goal of halting or reversing fibrosis progression and enhancing liver function. As an illustration, in March 2024, Madrigal Pharmaceuticals, Inc., a US-based biopharmaceutical company, announced the FDA approval of Rezdiffra (resmetirom), which stands as the first-ever treatment for metabolic dysfunction-associated steatohepatitis (MASH) with moderate to severe liver fibrosis. Rezdiffra is a daily oral tablet that exhibited effectiveness in resolving MASH without fibrosis worsening and improving liver fibrosis during phase 3 clinical trials. This significant advance provides a non-invasive treatment alternative, doing away with the necessity for liver biopsies, and substantially improves patient access and outcomes in managing fatty liver disease.
Which Major Industry Participants Are Leading The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Growth?
Major companies operating in the metabolic dysfunction-associated steatohepatitis (mash) treatment market are Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Sanofi SA, AstraZeneca PLC, Novartis AG, Eli Lilly and Company, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Apollo Health and Lifestyle Limited, Jenny Craig, Nutrisystem, Madrigal Pharmaceuticals, Anoos Clinic, Galectin Therapeutics Inc., Galmed Pharmaceuticals, Hepion Pharmaceuticals, Inventiva, NGM Biopharmaceuticals, Sagimet Biosciences, Viking Therapeutics, Terns Pharma, Genfit SA
Access The Complete Report For Deeper Market Insights:
Which Region Currently Holds The Largest Share Of The Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market?
North America was the largest region in the metabolic dysfunction-associated steatohepatitis (MASH) treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the metabolic dysfunction-associated steatohepatitis (mash) treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=20876&type=smp
Browse Through More Reports Similar to the Global Metabolic Dysfunction-Associated Steatohepatitis (MASH) Treatment Market 2026, By The Business Research Company
Fatty Liver Treatment Market Report 2026
https://www.thebusinessresearchcompany.com/report/fatty-liver-treatment-global-market-report
Non Alcoholic Steatohepatitis Treatment Market Report 2026
Non Alcoholic Steatohepatitis Biomarkers Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
